Key facts
- This page summarizes Robert Kramer's Form 4 filing for Emergent BioSolutions Inc. (EBS).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 27 Feb 2023, 19:22.
Robert Kramer - 23 Feb 2023 Form 4 Insider Report for Emergent BioSolutions Inc. (EBS)
- Reporting relationship
- President and CEO, Director
- Issuer ticker
- EBS
- Reported as of
- 23 Feb 2023
- Net transaction value
- -$42,233
- SEC form
- 4
- Accepted by SEC
- 27 Feb 2023, 19:22:02 UTC
- Prior SEC filing
- 10 Feb 2023
- Next SEC filing
- 02 Mar 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jennifer Lynn Fox, Attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Robert Kramer filed Form 4 for Emergent BioSolutions Inc. (EBS) on 27 Feb 2023.
Change
- Previous filing in this sequence was filed on 10 Feb 2023.
- Current net transaction value: -$42,233.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
EBS
transaction
Common Stock
Tax liability
- Transaction value
- $20,420
- Shares
- -1,428
- Change %
- -1.3%
- Price
- $14.30
- Shares after
- 108,115
- Date
- 23 Feb 2023
- Ownership
- Direct
- Footnotes
- F1
EBS
transaction
Common Stock
Tax liability
- Transaction value
- $21,813
- Shares
- -1,591
- Change %
- -1.5%
- Price
- $13.71
- Shares after
- 106,524
- Date
- 24 Feb 2023
- Ownership
- Direct
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
Represents shares of common stock withheld to pay taxes.